- Home
- LNT vs EXAS Comparison
LNT vs EXAS Comparison
Compare LNT & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- EXAS
- Stock Information
- Founded
- LNT 1917
- EXAS 1995
- Country
- LNT United States
- EXAS United States
- Employees
- LNT N/A
- EXAS N/A
- Industry
- LNT Power Generation
- EXAS Medical Specialities
- Sector
- LNT Utilities
- EXAS Health Care
- Exchange
- LNT Nasdaq
- EXAS Nasdaq
- Market Cap
- LNT 14.8B
- EXAS 12.3B
- IPO Year
- LNT N/A
- EXAS N/A
- Fundamental
- Price
- LNT $63.46
- EXAS $52.91
- Analyst Decision
- LNT Buy
- EXAS Strong Buy
- Analyst Count
- LNT 7
- EXAS 17
- Target Price
- LNT $62.50
- EXAS $73.07
- AVG Volume (30 Days)
- LNT 2.1M
- EXAS 3.6M
- Earning Date
- LNT 10-31-2024
- EXAS 11-05-2024
- Dividend Yield
- LNT 3.02%
- EXAS N/A
- EPS Growth
- LNT N/A
- EXAS N/A
- EPS
- LNT 2.57
- EXAS N/A
- Revenue
- LNT $3,966,000,000.00
- EXAS $2,692,328,000.00
- Revenue This Year
- LNT $5.29
- EXAS $12.41
- Revenue Next Year
- LNT $2.85
- EXAS $11.64
- P/E Ratio
- LNT $24.70
- EXAS N/A
- Revenue Growth
- LNT N/A
- EXAS 11.91
- 52 Week Low
- LNT $46.80
- EXAS $40.62
- 52 Week High
- LNT $63.62
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- LNT 65.20
- EXAS 35.92
- Support Level
- LNT $59.40
- EXAS $48.72
- Resistance Level
- LNT $60.53
- EXAS $54.55
- Average True Range (ATR)
- LNT 1.24
- EXAS 2.91
- MACD
- LNT 0.50
- EXAS -0.14
- Stochastic Oscillator
- LNT 99.03
- EXAS 19.71
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.